: T2 Biosystems’ stock extends losing streak despite FDA approval for anthrax and plague diagnostic test

by | Sep 20, 2023 | Stock Market

Shares of T2 Biosystems Inc. extended their losing streak to two days Wednesday despite the biotech clinching regulatory approval for a key diagnostic test. In a statement Tuesday, T2 Biosystems TTOO announced that it has received 510(k) clearance from the FDA for its T2Biothreat panel. The panel is a direct-from-blood molecular diagnostic test that detects six biothreat pathogens, including the organisms that cause anthrax, plague and typhus. With…

Article Attribution | Read More at Article Source

Share This